Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Change in Cash (2018 - 2025)

Entera Bio has reported Change in Cash over the past 8 years, most recently at -$1.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 198.57% year-over-year to -$1.7 million, compared with a TTM value of $6.2 million through Dec 2025, up 364.26%, and an annual FY2025 reading of $6.2 million, up 364.26% over the prior year.
  • Change in Cash came in at -$1.7 million for Q4 2025, up from -$2.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $11.9 million in Q1 2025 to a low of -$4.8 million in Q1 2022.
  • Median Change in Cash over the past 5 years was -$1.7 million (2023), compared with a mean of $313700.0.
  • The largest YoY upside for Change in Cash was 750.93% in 2025 against a maximum downside of 1337.82% in 2025.
  • Over 5 years, Change in Cash stood at -$2.5 million in 2021, then increased by 19.47% to -$2.0 million in 2022, then soared by 269.27% to $3.4 million in 2023, then plummeted by 48.75% to $1.7 million in 2024, then crashed by 198.57% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Change in Cash are -$1.7 million (Q4 2025), -$2.3 million (Q3 2025), and -$1.7 million (Q2 2025).